Cargando…
77. Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens
BACKGROUND: The single-tablet regimen (STR) dolutegravir/rilpivirine (DTG/RPV) was approved in 2017 for use in virologically suppressed PWH, followed by approval in 2019 of dolutegravir/lamivudine (DTG/3TC). There is a need to evaluate outcomes of 2DR regimens in stable switch population by measurin...
Autores principales: | Sax, Paul, Eron, Joseph J, Radtchenko, Janna, Diaz-Cuervo, Helena, Moore, Mark, Santiago, Steven, Ramgopal, Moti, Mounzer, Karam, Elion, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644888/ http://dx.doi.org/10.1093/ofid/ofab466.077 |
Ejemplares similares
-
LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)
por: Sax, Paul, et al.
Publicado: (2020) -
1592. Real-World Utilization and Effectiveness of Long-Acting Cabotegravir + Rilpivirine Among People with HIV with Detectable Viral Loads at Initiation: Trio Cohort Study
por: Elion, Rick A, et al.
Publicado: (2023) -
550. Adherence and Persistency With Modern Single vs. Multi-Tablet Antiretroviral (ARV) Regimens in First Treatment of HIV in Clinical Practice
por: Mills, Anthony, et al.
Publicado: (2018) -
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV
por: Patel, Sonia Vibhakar, et al.
Publicado: (2020) -
2087. Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
por: Elion, Rick A, et al.
Publicado: (2022)